Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.82 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.82 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.82 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.82 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.82 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.82 |
| ▸ | TSHR | P16473 | 1/20 | 0.82 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.82 |
| ▸ | DRD4 | P21917 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.79 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61848 | 0.94 | TMEM97 (0.83) | SIGMAR1TMEM97SLC6A12MCHR1CYP1A2 | |
| SCHEMBL31736417 | 0.93 | MCHR1 (0.77) | SIGMAR1TMEM97SLC6A12MCHR1CYP1A2 | |
| SCHEMBL9870172 | 0.92 | MEN1 (0.78) | SIGMAR1TMEM97SLC6A12MCHR1CYP1A2 | |
| SCHEMBL2233466 | 0.92 | KCNH2 (0.80) | SIGMAR1TMEM97SLC6A12MCHR1CYP1A2 | |
| SCHEMBL7218186 | 0.92 | DRD4 (0.86) | SIGMAR1TMEM97SLC6A12MCHR1CYP1A2 | |
| SCHEMBL7694198 | 0.92 | DRD2 (0.85) | SIGMAR1TMEM97SLC6A12MCHR1CYP1A2 | |
| SCHEMBL7694199 | 0.92 | DRD2 (0.85) | SIGMAR1TMEM97SLC6A12MCHR1CYP1A2 | |
| SCHEMBL2233461 | 0.91 | TMEM97 (0.77) | SIGMAR1TMEM97SLC6A12MCHR1CYP1A2 | |
| SCHEMBL8274001 | 0.91 | MEN1 (0.78) | SIGMAR1TMEM97SLC6A12MCHR1CYP1A2 | |
| SCHEMBL7224869 | 0.91 | SIGMAR1 (0.77) | SIGMAR1TMEM97SLC6A12MCHR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2012-05-10 | — | — | US | disclosed |
| EP-2421828-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF RENIN | Cadila Healthcare Limited (IN) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122580-A2 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | CADILA HEALTHCARE LIMITED (IN) | 2010-10-28 | — | — | WO | disclosed |
| EP-1012147-B1 | O-SUBSTITUTED HYDROXYCUMARANONE DERIVATIVES AS ANTITUMOR AND ANTIMETASTATIC AGENTS | HOFFMANN LA ROCHE (CH) | 2005-11-02 | — | — | EP | disclosed |
| EP-1021185-A4 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-24 | — | — | US | disclosed |
| US-6245773-B1 | BENIGN PROSTATIC HYPERPLAMIA; REDUCTION OF INTRAOCULAR PRESSURE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-06-12 | — | — | US | disclosed |
| US-6200989-B1 | ADMINISTERING AS UROKINASE PLASMINOGEN ACTIVATOR ANTAGONISTS, ANTITUMOR AND ANTIMETASTASIS AGENTS | HOFFMANN-LA ROCHE INC. | 2001-03-13 | — | — | US | disclosed |
| EP-1021185-A1 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0880512-A1 | NOVEL AROMATIC PIPERAZINES DERIVED FROM SUBSTITUTED CYCLOAZANES, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 1998-12-02 | — | — | EP | disclosed |
| WO-1998051311-A2 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-11-19 | — | — | WO | disclosed |
| WO-1997042956-A1 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| WO-1997028141-A1 | NOVEL AROMATIC PIPERAZINES DERIVED FROM SUBSTITUTED CYCLOAZANES, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 1997-08-07 | — | — | WO | disclosed |
| US-5028616-A | Antiarrhythmia Agents | G. D. SEARLE & CO. (US) | 1991-07-02 | — | — | US | disclosed |
| EP-0008014-A1 | 1-(4-Aminopiperidino)-3.4-dihydroisoquinoline derivatives, processes for their preparation, pharmaceutical compositions containing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115907-A1 | NOVEL COMPOUNDS AS INHIBITORS OF RENIN | REN, ACE, AGTR1 | SIGMAR1 3798/4885TMEM97 4636/4885SLC6A12 3089/4885 |
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | SIGMAR1 534/4885TMEM97 501/4885SLC6A12 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.